The Effectiveness of Microdosed Psilocybin in the Treatment of Neuropsychiatric Lyme Disease: A Case Study
Authors Kinderlehrer DA
Published 3 March 2023 Volume 2023:16 Pages 109—115
DOI https://doi.org/10.2147/IMCRJ.S395342
Review by Single anonymous peer review
Daniel A Kinderlehrer
Private Practice, Denver, CO, USA
Correspondence: Daniel A Kinderlehrer, Email kinderlehrer@gmail.com
Abstract: Lyme disease can result in severe neuropsychiatric symptoms that may be resistant to treatment. The pathogenesis of neuropsychiatric Lyme disease is associated with autoimmune induced neuroinflammation. This case report describes an immunocompetent male with serologically positive neuropsychiatric Lyme disease who did not tolerate antimicrobial or psychotropic medications and whose symptoms remitted when he began psilocybin in microdosed (sub-hallucinogenic) amounts. A literature review of its therapeutic benefits reveals that psilocybin is both serotonergic (affecting serotonin) and anti-inflammatory and therefore may offer significant therapeutic benefits to patients with mental illness secondary to autoimmune inflammation. The role of microdosed psilocybin in the treatment of neuropsychiatric Lyme disease and autoimmune encephalopathies warrants further study.
For more:
- https://www.drugscience.org.uk/drug-information/psilocybin/ Excerpt: Psilocybin mushrooms are naturally occurring mushrooms which contain the psychoactive compound psilocybin. More than 180 psilocybin-containing mushrooms species are found all over the world and can induce hallucinogenic/psychedelic effects when consumed. Psilocybin is converted by the body to psilocin, and this is the actual compound which produces their psychoactive effects. Additional chemicals commonly present in minor amounts include baeocystin and norbaeocystin, although the extent to which these contribute to the overall effects is unclear.The small and potent liberty cap mushroom (Psilocybe semilanceata) is probably the most common and widespread species found in Europe. Other species occur in the wild, and Psilocybe cubensis is cultivated indoors.
- https://madisonarealymesupportgroup.com/2020/02/29/woman-tripped-34-hours-on-lsd-said-it-cured-pain-from-chronic-lyme-disease/
- https://madisonarealymesupportgroup.com/2020/12/07/repurposing-disulfiram-in-the-treatment-of-lyme-disease-and-babesiosis-retrospective-review-of-first-3-years-experience-in-one-medical-practice/
- https://madisonarealymesupportgroup.com/2016/02/13/lyme-disease-treatment/